Market Overview

Bristol-Myers, Pfizer Report Stroke, Systemic Embolism, Major Bleeding Uncommon in Eliquis Phase 3 ARISTOTLE Trial

Share:
Related BMY
Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers
These Were The Most Popular Buys And Sells Among Retail Investors In June
The Vetr community has upgraded $BMY to 4.5-Stars. (Vetr)

Bristol-Myers
Squibb Company (NYSE: BMY) and Pfizer
Inc. (NYSE: PFE) today announced results of a post-hoc subanalysis
from the Phase III ARISTOTLE trial. Patients with nonvalvular atrial
fibrillation (NVAF) who are anticoagulated to reduce the risk of stroke
often undergo procedures for which temporary discontinuation of the
anticoagulant prior to and following the procedure is sometimes
warranted. This subanalysis describes the overall rates of key
post-procedural outcomes, such as stroke or systemic embolism and major
bleeding, among Eliquis and warfarin patients who underwent a
procedure during the ARISTOTLE trial, and examined any differences in
post-procedural events according to whether or not study drug was
interrupted. This subanalysis was presented today at the ESC

See full press release

Posted-In: News Guidance Contracts Management M&A Global

 

Related Articles (BMY + PFE)

View Comments and Join the Discussion!